BeiGene, Ltd.

BGNE

BGNE has 23 disclosed filings on Paydirt over the past 24 months from 7 corporate insiders: 0 purchases and 23 sales. Filers took a median of 2 days from execution to disclosure, and the most recent trade was executed May 13 2025 and filed May 15 2025. The most active filer was Xiaodong Wang with 8 filings.

Add to watchlist

Filings, 24m

0 buys · 23 sells

Traders, 24m

7 insiders

Volume, 24miDollar value disclosed in the window

$367.1M

estimated for Congress, as filed for insiders

Median delay

execution to disclosure

Last traded

May 13 2025

Filed May 15 2025

ADViAverage daily dollar volume

–

not on file

No price series on file for BGNE yet.

Volume by month

Buys $0 Sells $367.1M

Estimated for Congress, as filed for insiders · by filing month · past 24 months

Who filed

XW Xiaodong Wang Director 8 filings JO

John Oyler Chief Executive Officer 5 filings CL

Chan Henry Lee SVP, General Counsel 3 filings XW

Xiaobin Wu President, COO & GM China 3 filings LW

Lai Wang President, Global Head of R&D 2 filings BL Baker Brothers Life Sciences LP Director 1 filing HL Hillhouse Investment Management, Ltd. 10% owner 1 filing

Recent filings

Xiaodong WangSALE Director $9.3M
41,560 sh across 3 lots
Exec May 13 2025
Filed May 15 2025 · 5:30 PM ET Xiaodong WangSALE Director $10.0M
41,395 sh across 12 lots
Exec Apr 14 2025
Filed Apr 16 2025 · 5:30 PM ET Xiaobin WuSALE President, COO & GM China $14.6M
51,921 sh across 4 lots
Exec Apr 1 2025
Filed Apr 3 2025 · 5:30 PM ET Xiaodong WangSALE Director $10.9M
41,760 sh across 7 lots
Exec Mar 18 2025
Filed Mar 20 2025 · 5:30 PM ET John OylerSALE Chief Executive Officer $10.0M
41,210 sh across 9 lots
Exec Mar 10 2025
Filed Mar 12 2025 · 5:30 PM ET Xiaobin WuSALE President, COO & GM China $13.5M
51,721 sh across 3 lots
Exec Mar 5 2025
Filed Mar 7 2025 · 5:30 PM ET John OylerSALE Chief Executive Officer $10.4M
40,009 sh across 7 lots
Exec Mar 6 2025
Filed Mar 7 2025 · 5:30 PM ET John OylerSALE Chief Executive Officer $14.6M
58,590 sh across 13 lots
Exec Mar 7 2025
Filed Mar 7 2025 · 5:30 PM ET Xiaodong WangSALE Director $2.0M
7,823 sh across 6 lots
Exec Mar 4 2025
Filed Mar 6 2025 · 5:30 PM ET John OylerSALE Chief Executive Officer $24.7M
101,000 sh across 12 lots
Exec Mar 3 2025
Filed Mar 5 2025 · 5:30 PM ET Chan Henry LeeSALE SVP, General Counsel $331K
1,205 sh × $275.00
Exec Feb 27 2025
Filed Mar 3 2025 · 5:30 PM ET Chan Henry LeeSALE SVP, General Counsel $284K
1,102 sh across 2 lots
Exec Feb 21 2025
Filed Feb 25 2025 · 5:30 PM ET Lai WangSALE Global Head of R&D $1.3M
5,000 sh across 6 lots
Exec Feb 21 2025
Filed Feb 25 2025 · 5:30 PM ET Xiaobin WuSALE President, COO & GM China $12.5M
51,921 sh across 4 lots
Exec Feb 18 2025
Filed Feb 20 2025 · 5:30 PM ET Xiaodong WangSALE Director $9.4M
41,760 sh across 6 lots
Exec Feb 4 2025
Filed Feb 6 2025 · 5:30 PM ET Xiaodong WangSALE Director $7.4M
41,760 sh across 5 lots
Exec Jan 7 2025
Filed Jan 8 2025 · 5:30 PM ET Xiaodong WangSALE Director $7.7M
41,460 sh across 10 lots
Exec Dec 10 2024
Filed Dec 12 2024 · 5:30 PM ET Baker Brothers Life Sciences LPSALE Director $194.2M
1,037,017 sh across 4 lots
Exec Dec 9 2024
Filed Dec 10 2024 · 5:30 PM ET Hillhouse Investment Management, Ltd.SALE 10% owner –
17,842,500 sh · price not plausible
Exec Dec 2 2024
Filed Dec 4 2024 · 5:30 PM ET Xiaodong WangSALE Director $8.9M
47,044 sh across 13 lots
Exec Nov 26 2024
Filed Nov 29 2024 · 5:30 PM ET John OylerSALE Chief Executive Officer $3.6M
15,475 sh across 10 lots
Exec Oct 8 2024
Filed Oct 10 2024 · 5:30 PM ET Chan Henry LeeSALE SVP, General Counsel $285K
1,202 sh × $237.10
Exec Sep 30 2024
Filed Oct 2 2024 · 5:30 PM ET Lai WangSALE Global Head of R&D $1.1M
5,000 sh × $220.35
Exec Sep 27 2024
Filed Oct 1 2024 · 5:30 PM ET Xiaobin WuSALE President, COO & GM China $1.0M
5,000 sh across 2 lots
Exec Sep 17 2024
Filed Sep 19 2024 · 5:30 PM ET